Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
110.67
+3.05 (2.83%)
At close: Jun 27, 2025, 4:00 PM
110.70
+0.03 (0.03%)
After-hours: Jun 27, 2025, 7:41 PM EDT
Gilead Sciences Revenue
Gilead Sciences had revenue of $6.67B in the quarter ending March 31, 2025, a decrease of -0.28%. This brings the company's revenue in the last twelve months to $28.74B, up 4.68% year-over-year. In the year 2024, Gilead Sciences had annual revenue of $28.75B with 6.04% growth.
Revenue (ttm)
$28.74B
Revenue Growth
+4.68%
P/S Ratio
4.80
Revenue / Employee
$1,632,670
Employees
17,600
Market Cap
137.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
GILD News
- 14 hours ago - Gilead shares rise after US top court ruling on preventative coverage - Reuters
- 2 days ago - Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - Reuters
- 2 days ago - Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Business Wire
- 9 days ago - AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention - Business Wire
- 9 days ago - Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - Business Wire
- 9 days ago - FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC
- 9 days ago - US FDA approves Gilead's twice-yearly injection for HIV prevention - Reuters
- 9 days ago - Should You Buy Gilead Stock At $110? - Forbes